ECTRIMS 2025: Some older adults with MS may safely stop DMTs
Some older people with multiple sclerosis (MS), namely those older than 60, may be able to safely discontinue…
Articles by Lindsey Shapiro, PhD
ECTRIMS 2025: Stem cell transplant beats DMTs at lowering risk of PIRA
A stem cell transplant may offer better long-term results for people with aggressive multiple sclerosis (MS) compared with standard…
New AI model challenges how multiple sclerosis is classified
A new model using artificial intelligence (AI) suggests that multiple sclerosis (MS) progression is better viewed along a single…
MS patients at lower risk for some digestive cancers, study finds
While certain autoimmune diseases are linked to an increased risk of digestive system cancers, people with multiple sclerosis (MS)…
MS patients increasingly use diet to manage symptoms: Study
More people with multiple sclerosis (MS) are using diet modifications to boost well-being and to manage symptoms, but there’s…
Experts call for better care, research tailored for older MS patients
Experts are calling for tailored strategies to enhance the diagnosis, treatment, and monitoring of older people with multiple sclerosis…
New global trial testing oral therapy BMS-986368 for MS spasticity
A global clinical trial has been launched to evaluate the oral therapy candidate BMS-986368 for treating spasticity — muscle…
EBV antibody test can predict MS years before symptom onset
Researchers have developed a blood test to identify people at risk of developing multiple sclerosis (MS) years before the…
Algorithm to analyze smartphone app data can predict MS symptoms
Artificial intelligence (AI)-powered algorithms to analyze data collected on a smartphone app could predict whether a person with multiple…
T-cells help protect against risk of COVID-19 infection in MS: Study
The use of B-cell depleting therapies does not increase the risk of an infection with COVID-19 among people with…
MRI finding may reduce need for invasive spinal tap to diagnose MS
A particular finding on an MRI scan, called the central vein sign (CVS), is sufficient to support a multiple…
2 researchers win Breakthrough Prize for MS discoveries
A pair of scientists have been awarded a 2025 Breakthrough Prize in Life Sciences for their work uncovering factors that…
AAN 2025: Gains from CNM-Au8 in RRMS linked to nerve cell repair
Clinical improvements in vision and cognition linked to the use of treatment candidate CNM-Au8 were correlated with signs of…
High-dose vitamin D may stop CIS, early RRMS new disease activity
A high dose cholecalciferol, a form of vitamin D, significantly reduced the risk of further disease activity in people…
Signs of damage over time may not be needed for MS diagnosis: Study
Evidence of neurological damage over time — known as dissemination in time, or DIT — may not be necessary to…
Cells in MS lesions found to acquire mutations faster than healthy cells
Neurons, also called nerve cells, collected from brain lesions of people with multiple sclerosis (MS) were found to…
ACTRIMS 2025: Updated McDonald criteria could aid MS diagnosis
Proposed revisions to the McDonald criteria, a set of diagnostic guidelines for multiple sclerosis (MS), may help diagnose…
ACTRIMS 2025: Ketogenic diet alters immune cell function
Note: This study was updated March 3, 2025, to correct that a ketogenic diet is a low-carbohydrate, high-fat diet.
ACTRIMS 2025: Ocrevus may help treat MS paramagnetic rim lesions
Treatment with Ocrevus (ocrelizumab) may have a beneficial effect on paramagnetic rim lesions — known as PRL, these are…
ACTRIMS 2025: Immune profiles imply EBV reactivation in relapses
Immune cells from people with multiple sclerosis (MS) exhibit distinct gene activity just before patients have a disease…
Delaying start of DMTs in RRMS tied to low educational attainment
Relapsing-remitting multiple sclerosis (RRMS) patients with low educational attainment are more likely to delay the start of disease-modifying…
Cognition improves, other MS symptoms ease with acupuncture
A three-month course of acupuncture was associated with gains in certain aspects of cognition for people with relapsing-remitting multiple…
PoNS device leads to long-term gait improvements: Real-world study
A 14-week regimen of physical therapy combined with PoNS — a neurostimulator device used to improve mobility — led…
Immunic ‘on track’ with MS clinical trials testing vidofludimus calcium
Immunic Therapeutics says it remains “on track” in testing its multiple sclerosis treatment candidate vidofludimus calcium in twin Phase…
Genetics, environment may interact to affect early brain development
An interplay between genetic and environmental risk factors, including tobacco smoke exposure, affects brain development in early childhood, which could…
Factors found to affect NfL levels, a biomarker used in MS research
Blood levels of neurofilament light chain (NfL) — a biomarker of nerve cell damage used in multiple sclerosis (MS)…
Roche to buy Poseida, building on CAR-T cell collaboration
Roche signed a definitive agreement to acquire Poseida Therapeutics, a deal that includes Poseida’s portfolio of CAR T-cell therapy candidates…
Scientists ID mechanisms that could drive neurodegeneration in MS
Activation of a protein called DLK may drive the death of nerve cells that have been demyelinated, or lost their…
Prevalence of MS accelerating in Australia in recent years: Report
The number of people living with multiple sclerosis (MS) in Australia rose by more than 50% in the decade…
Vidofludimus calcium trials continue as planned after panel review
An independent data monitoring committee has recommended that the twin ENSURE Phase 3 trials testing vidofludimus calcium in people…